Matching adjusted indirect comparison addresses key questions and limitations associated with previously presented analysis and suggests efficacy advantage of BRUKINSA vs acalabrutinib In this MAIC, ...

Please provide your email address to receive an email when new articles are posted on . Fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, improved survival compared with ...

AstraZeneca ($AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a Phase 3b, multicenter, ...

Medical experts illustrate the impact of combination therapy for treatment of CLL and SLL. This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara ...

SAN DIEGO — Treatment with the oral Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib in combination with venetoclax was associated with improved progression-free survival compared with ...

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone First and only BTK inhibitor approved for the 1st-line ...

Please provide your email address to receive an email when new articles are posted on . Time-limited, dual B-cell receptor inhibitor therapy seems promising in treatment-naive and relapsed/refractory ...

Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of ...

Lori A. Leslie, MD: We now have 3 covalent BTK [Bruton tyrosine kinase] inhibitors approved in CLL [chronic lymphocytic leukemia]. We talked a bit about the frontline setting, and the ...